Bristol-Myers Squibb Company is a Delaware corporation that discovers, develops, licenses, manufactures, markets and sells prescription medicines, with a focus on oncology, hematology, immunology, cardiovascular disease and neuroscience. Its principal executive offices are at Route 206 & Province Line Road in Princeton, New Jersey. Its common stock trades on the New York Stock Exchange as BMY.
Identity
- Legal name (10-K cover): Bristol-Myers Squibb Company
- Ticker and exchange: BMY, New York Stock Exchange
- State of incorporation: Delaware (incorporated August 1933 as Bristol-Myers Company, successor to a New York business started in 1887; renamed Bristol-Myers Squibb Company in 1989)
- SEC CIK: 0000014272 (SEC commission file number 001-01136)
- Fiscal year end: December 31
- Category: Pharmaceuticals and life sciences; biopharmaceutical company
Business structure and 2025 revenue
The Form 10-K for the year ended December 31, 2025 states that Bristol Myers Squibb operates in a single segment. Total revenues were $48,194 million: 69% in the United States, 29% international and 2% other (royalties and alliance-related revenue). The 10-K splits product revenue into a Growth Portfolio of $26,409 million and a Legacy Portfolio of $21,785 million.
| Product (10-K portfolio) | 2025 revenue (USD millions) |
|---|---|
| Eliquis (Legacy) | 14,443 |
| Opdivo (Growth) | 10,049 |
| Orencia (Growth) | 3,705 |
| Revlimid (Legacy) | 2,951 |
| Yervoy (Growth) | 2,900 |
| Pomalyst/Imnovid (Legacy) | 2,733 |
| Reblozyl (Growth) | 2,327 |
The 10-K describes the research platforms as small molecules including protein degraders, biologics, antibody-drug conjugates, CAR-T cell therapies and radiopharmaceutical therapeutics. It names significant manufacturing operations in the U.S., Puerto Rico, the Netherlands, Ireland and Switzerland.
Workforce and sites
As of December 31, 2025, the company had approximately 32,500 employees in 43 countries, 54% of them in the U.S. (excluding Puerto Rico) and 46% outside the U.S. It owns or leases facilities at approximately 130 sites worldwide and lists 8 significant manufacturing locations and 8 significant R&D locations (4 manufacturing and 7 R&D in the U.S.).
How to verify this company yourself
- SEC EDGAR filer page for Bristol-Myers Squibb Company (CIK 0000014272)
- Form 10-K for fiscal year 2025 (cover page, Item 1 business, Item 2 properties)
- Bristol Myers Squibb official contact page (mailing address, customer relations, side-effect reporting, medical information)
- Bristol Myers Squibb investor relations site
Location and contact
- Corporate headquarters and principal executive offices (10-K cover; same on bms.com/contact-us.html): Route 206 & Province Line Road, Princeton, NJ 08543
- Registrant telephone (10-K cover): +1 609-252-4621
- Customer and community relations (bms.com/contact-us.html; toll free, U.S. only): +1 800-332-2056
- Website: bms.com
Last verified: November 6, 2026. Sources: Bristol-Myers Squibb Form 10-K for fiscal 2025 (filed February 11, 2026); SEC EDGAR submissions record for CIK 0000014272; bms.com contact page; investors.bms.com.
Directory listing. Not investment advice, not a product review, and not medical advice. Product names and revenue figures are those published in the company’s 10-K.
Listing type: Editorial. Not claimed by the company. Not sponsored. Send a correction.
